SCC denies Apotex leave to appeal ramipril pleadings amendment decision
As previously reported, Apotex sought leave to appeal a decision of the Ontario Court of Appeal (2018 ONCA 890) permitting Sanofi and Schering to amend their defences to claims under the Ontario Statute of Monopolies, U.K. Statute of Monopolies and Trade-Marks Act. Apotex’s claims rely on Sanofi-Aventis Canada v Apotex Inc, 2009 FC 676 (“invalidity decision”), which found certain claims of Canadian Patent No. 1,341,206 invalid on the basis of the “promise doctrine”. The ONCA permitted Sanofi and Schering to plead that AstraZeneca Canada Inc. v Apotex Inc, 2017 SCC 36 – which rejected the promise doctrine as “unsound” – rendered the invalidity decision suspect. On May 16, 2019, the Supreme Court denied Apotex’s application for leave to appeal (Case No. 38471).
SCC denies Apotex leave to appeal cefaclor damages decision re: non-infringing alternative defence
As previously reported, Apotex sought leave to appeal a decision of the Federal Court of Appeal (2018 FCA 217) relating to damages awarded to Eli Lilly in respect of Apotex’s infringement of process patents relating to cefaclor. The FCA concluded that a non-infringing alternative defence was not available to Apotex. On May 23, 2019, the Supreme Court denied Apotex’s application for leave to appeal (Case No. 38485).
Related Publications & Articles
-
Update on biosimilars in Canada – June 2025
This article provides an update on developments in the biosimilar space in Canada—regulatory, approvals, pending submissions, litigation, and market access.Read More -
Health Canada must redetermine exemption requests for psilocybin (magic mushroom)-assisted psychotherapy training
TheraPsil, a patient advocacy organization, and 73 healthcare practitioners (HCPs) have succeeded in the Federal Court of Appeal to overturn the refusal of the Minister of Mental Health and Addictions...Read More -
2025 mid-year highlights in Canadian life sciences IP and regulatory law
In the first half of 2025, the Rx IP Update team reported on a number of developments in Canadian life sciences IP and regulatory law. Below are our top stories.Read More